Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies

NCT04994626 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

DLBCL
MYD88 Gene Mutation
CD79A Gene Mutation
CD79B Gene Mutation
Relapse
Refractory Lymphoma

Interventions

DRUG: Ibrutinib Combined With Rituximab

Sponsor

Chinese Academy of Medical Sciences